Human papillomaviruses (HPV) are a major cause of malignancy worldwide They 24 are the aetiological agent of almost all cervical cancers and an increasing number of 25 head and neck carcinomas. Deregulation of the Hippo pathway component YAP1 26 has recently been demonstrated to play a role in HPV-mediated cervical cancer, but 27 whether other components of this pathway are implicated in the pathogenesis of this 28 disease remains poorly understood. 29
The expression level and activation status of critical Hippo pathway components 30 were analysed across multiple cytology samples from patients with cervical disease, 31 as well as HPV positive (HPV+) and HPV negative (HPV-) cervical cancer cell lines 32 using real time qPCR, western blot and immunohistochemistry. In parallel, we 33 assessed the effects of MST1 and MST2 overexpression upon cervical cancer cell 34 proliferation, migration and invasion. Finally, we interrogated the consequences of 35 interrupted MST1 and MST2 function using a targeted small molecule inhibitor in 36 tandem with kinase inactive MST mutants. Our analysis found that expression of the 37 Ste20 kinase MST1 was decreased within both HPV+ primary patient samples and 38 cervical cancer cell lines. This effect was mediated by the virus-coded oncoproteins 39 E6 and E7, which impair MST1 transcription. Reintroduction of MST1, or its 40 paralogue MST2, into HPV positive cervical cancer cells re-activated the Hippo 41 pathway, leading to a reduction in cell proliferation, migration and invasion. Finally, 42 using a small molecule inhibitor of MST1/2 or kinase inactive mutants of either 43 protein, we demonstrated that this effect required the kinase function of MST1/2. Our 44 results reveal that HPV down regulates MST1 expression to inactivate the Hippo 45 pathway and so drive cells towards transformation.
3 Introduction 47 Human papillomaviruses (HPV) are the major cause of cervical cancer, accounting 48 for 99.9% of all cases, as well as being linked to an increasing number of head and 49 neck carcinomas (1-3). The majority of HPV-associated cancer cases are caused by 50 infections with two high-risk (HR) types; HPV16 and HPV18, but other HPV types 51
can also cause cancer. The main drivers of transformation in HPV-mediated cancers 52 are the E6 and E7 oncoproteins. These oncoproteins interact with multiple host cell 53 factors to manipulate cellular processes and promote transformation (4-7). 54
The Hippo pathway is a major regulator of cellular homeostasis. In humans, the 55 canonical Hippo pathway consists of the Ste20 family kinases MST1 and MST2, 56 which are activated by phosphorylation in response to a wide range of upstream 57 factors (8). Activated MST1/2 subsequently phosphorylate the adaptor protein MOB1 58 and the Ste20 kinases LATS1 and LATS2, which in turn phosphorylate the 59 transcriptional regulators YAP1 and TAZ (9). Phosphorylation of YAP1 results in its 60 nuclear exclusion or proteosomal degradation (9). However, in their non-61 phosphorylated state, YAP1/TAZ traffic to the nucleus where they partner with TEAD 62 transcription factors to regulate the expression of genes controlling cell proliferation 63 (10). 64
The YAP gene is a bona fide oncogene, with a number of studies showing its 65 importance as a growth promoter (11, 12) . YAP1 is overexpressed in several 66 cancers, with increased expression linked to shorter patient survival (13-15). Studies 67 also show that loss of MST1/2 contributes to tumourigenesis. In mice, reduced 68 MST1/2 mRNA levels lead to hepatocellular carcinoma (16) and in colorectal 69 cancers, expression of micro-RNA miR-590-3p decreases MST1 expression (17). 70
One recent study recommended MST1 as an early biomarker for colorectal cancer 71 and as a marker for poor prognosis (18). 72
Despite the emerging paradigm of the Hippo pathway as a key mediator of 73 transformation, its role in cervical cancer is poorly understood. Recently, it was 74 demonstrated that the HPV E6 oncoprotein stabilises YAP protein expression, 75 thereby promoting cervical cancer progression (19). YAP stabilisation leads to an 76 increased expression of the epidermal growth factor receptor (EGFR) ligand, 77 amphiregulin (AREG), which in turn further inhibits the Hippo pathway (19). Whether 78 other components of the Hippo pathway are deregulated in cervical cancer is less 79
clear. 80
To gain further insights into the regulation of the Hippo pathway in cervical cancer 81 we firstly analysed the expression and activation of key components of the pathway 82 in a panel of cervical cancer cell lines. We demonstrated that MST1 expression is 83 selectively decreased in HPV positive (HPV+) cervical cancer cells when compared 84 with normal human keratinocytes (NHKs) or HPV negative (HPV-) cervical cancer 85 cells. Importantly, we showed that MST1 expression is also decreased in cytology 86 samples from patients with cervical disease and in cervical cancer samples. 87
Additionally, reintroduction of MST1, or its paralogue MST2, into HPV+ cancer cells 88 inhibits their proliferation, migration and invasion. Finally, we confirm that the tumour 89 suppressor activity of MST1 is dependent on its function as a protein kinase. 90
Together, we have identified a novel host factor targeted by HPV to drive cervical 91 cancer progression that may be a potential therapeutic target. 92
Materials and Methods

94
Cell culture 95
HeLa (HPV18+ cervical epithelial adenocarcinoma cells), SW756 (HPV18+ cervical 96 squamous carcinoma cells), SiHa (HPV16+ cervical squamous carcinoma cells), 97
CaSKi (HPV16+ cervical squamous carcinoma cells) and C33A (HPV-cervical 98 squamous carcinoma) cells obtained from the ATCC were grown in DMEM 99 supplemented with 10% FBS (ThermoFischer Scientific, USA) and 50 U/mL 100 penicillin. Normal human keratinocytes (NHKs) were maintained in serum free 101 medium (SFM; GIBCO, UK) supplemented with 25 µg/mL bovine pituitary extract 102 (GIBCO, UK) and 0.2 ng/mL recombinant EGF (GIBCO, UK). All cells were cultured 103 at 37°C and 5% CO 2 . Cells were negative for Mycoplasma contamination during this 104 investigation. Cell identify was confirmed by karyotype analysis. using QuantiFast SYBR Green PCR kit (Qiagen) and analysed using the ∆∆CT 137 method(21) normalised to the U6 housekeeping gene. Each experiment was 138 repeated at least 3 times. Primer sequences can be found in Table 1 . Human amphiregulin levels were detected in the cell supernatants using the 167 DuoSet® ELISA kit according to the manufacturer's instructions (R&D Systems). 168
Microarray analysis 169
For microarray analysis, a dataset of 28 cervical cancer cases and 23 normal cervix 170 samples was utilised. Microarray data was obtained from GEO database accession 171 number GSE9750. 172 173
Immunofluorescence Analysis 174
Cells were seeded onto coverslips and, 24 hr later, were transfected as required. 24 175 hr after transfection, cells were fixed with 4 % paraformaldehyde for 10 min and then 176 
Results
198
MST1 expression is selectively decreased in HPV+ cervical cancer cell lines 199
To investigate the regulation of the Hippo pathway in cervical cancer cells, we first 200 measured the protein expression and enzymatic activity of key components of the 201 pathway. Compared with normal primary human keratinocytes (NHKs) or the HPV-202 cervical cancer cell line C33A, levels of total YAP1 and the phosphorylated form of 203 YAP1 (pYAP1 S127) were significantly increased ( Figure 1A ), consistent with a 204 previous study linking increased YAP1 expression to cervical cancer(22). In these 205 experiments we also observed that MST1 protein expression was significantly lower 206 in both HPV16+ (SiHa p= 0.0087 and Caski p= 0.0044) and HPV18+ (SW756 p= 207 0.0052 and HeLa p= 0.0018) cervical cancer cell lines compared to NHK cells. 208
Levels of MST1 in the C33A cells were similar to those observed in the NHK cells 209 (p= 0.44) ( Figure 1A , quantified in B). The reduction in MST1 protein expression in 210 the HPV+ cell lines was accompanied by a decrease in phosphorylation of the MST1 211 substrate MOB1 ( Figure 1A) . 212
To extend these results to a physiologically relevant scenario we analysed cervical 213 liquid based cytology samples from a cohort of HPV16+ patients representing the 214 progression of disease development. Cervical intraepithelial neoplasia (CIN) 215 commonly precedes cervical cancer progression. CIN1 is thought to represent a 216 transient HPV infection, while CIN3 represents clinically significant HPV infection that 217 may progress to cervical cancer (23). Normal cytology samples from HPV-patients 218 served as controls in these experiments. By western blot we observed a significant 219 decrease in MST1 protein levels during cervical disease progression through the CIN 220 grades ( Figure 1C and quantified in 1D; CIN1 p>0.05; CIN2 p=0.012; CIN3 p=0.015). 221
We corroborated these findings using immunofluorescence microscopy to examine 222 MST1 protein expression in sections of cervical tissue from both low-grade CIN1 and 223 high-grade CIN3 samples. Analysis of the staining pattern showed a clear decrease 224 in MST1 protein staining in the CIN3 section; in agreement with the western blot data 225 ( Figure 1E ). Together, these data demonstrate that MST1 expression is selectively 226
MST1 expression is inhibited at the transcript level in HPV+ cervical cancer 229 cells 230
To investigate the mechanism by which MST1 expression is decreased in HPV+ 231 cervical cancer cells, we measured MST1 mRNA levels using qRT-PCR ( Figure 2A) . 232 MST1 mRNA levels were selectively decreased in both HPV16+ (SiHa p= 0.01 and 233
CaSKi p= 0.004) and HPV18+ (SW756 p= 0.001 and HeLa p= 0.05) cervical cancer 234 cell lines when compared with NHK and C33A cells (p= 0.12). Next, we extracted 235 RNA from cervical cytology samples and performed qRT-PCR analysis to determine 236 the levels of MST1 mRNA. In agreement with the protein data, there was a 237 significant decrease in MST1 mRNA levels during cervical disease progression 238 ( Figure 2B ; CIN1 p>0.05; CIN2 p=4.6x10 -7 ; CIN3 p=1.1x10 -5 ). Finally, we mined a 239 publically available database of microarray data comparing normal cervical samples 240 against those obtained from cervical cancer samples(24). In these samples, there 241 was a statistically significant decrease in MST1 mRNA expression in the cervical 242 cancer samples ( Figure 2C ; p=0.01). Together, these data demonstrated that MST1 243 levels are regulated at the mRNA level in HPV+ cervical cancer. 244
245
HPV E6 and E7 oncoproteins inhibit MST1 expression 246
The E6 and E7 oncoproteins are the key drivers of transformation in HPV+ cervical 247 cancers(6,25,26). We hypothesized that one of these oncoproteins may be 248 Figure 3B ). The combined 258 knockdown of both E6 and E7 led to the most substantial increase in MST1 259 expression ( Figure 3A ; lane 5 and quantification in Figure 3B ). We next used qRT-260 PCR to confirm if E6 and E7 regulate MST1 mRNA expression. In agreement with 261 our previous data, combination of E6 and E7 knockdown led to a significant increase 262 in MST1 mRNA expression in both HPV16+ and HPV18+ cervical cancer cell lines 263 ( Figure 3C ). Together, these data suggest that HR-HPV E6 and E7 regulate MST1 264 mRNA expression. 265
266
MST1/2 over expression activates Hippo signalling in HPV+ cancer cells 267
To assess the functional consequences of reduced MST1 expression in HPV+ 268 cervical cancer, we re-introduced MST1 and its paralogue MST2 into HeLa and 269
CaSKi cells. MST2 shares 75% similarity to MST1 and the two proteins are thought 270 to share some functions (28). Transfection of Myc-tagged MST1 or MST2 led to a 271 significant increase in the phosphorylation of MOB1 and YAP1, indicating that re-272 introduction of MST1 or MST2 activates the Hippo pathway ( Figure 4A and 273
Supplementary Figure 1A) . Activated Hippo signalling decreases YAP1 localisation 274 to the nucleus, inhibiting YAP1 transcriptional activity. We therefore used 275 immunofluorescence microscopy to visualise YAP1 levels and localisation in HeLa Figure 4C and Supplementary Figure 1C ). Expression of either MST1 or 284 MST2 led to a similar decrease in the mRNA levels of these YAP-dependent genes. 285
To confirm these data, we performed an ELISA for amphiregulin levels in the culture 286 medium of cells overexpressing MST1 or MST2. Amphiregulin levels in the culture 287 medium were reduced on average 50% in cells overexpressing MST1 and 60% in 288 cells expressing MST2 ( Figure 4D and Supplementary Figure 1D 
MST1/2 inhibits proliferation and cell cycle progression of HPV+ cancer cells 294
The Hippo pathway negatively regulates tumour progression in a number of cancers. 295
Given this information, we felt it pertinent to investigate the consequences of re-296 activating Hippo signalling in HPV+ cervical cancer cells by the re-introduction of 297 MST1 or MST2. Compared to HeLa and CaSKi cells transfected with empty 298 expression plasmid, re-introduction of either MST1 or MST2 resulted in a significant 299 decrease in cell proliferation ( Figure 5A and Supplementary Figure 2A To further evaluate the impact of MST overexpression, we assessed the levels of 304 cyclin proteins, which drive cell proliferation. Upon re-activation of the Hippo 305 pathway, there was a decrease in cyclin B1 and cyclin D1 protein levels but no 306 change in cyclin E expression ( Figure 5D and Supplementary Figure 2D Together, these data show that Hippo re-activation results in a defect in cell 314 proliferation and the ability of HeLa and CaSKi cells to form colonies in an anchorage 315 dependent or independent manner, highlighting a potential tumour suppressor role 316 for MST proteins in HPV+ cervical cancer cells. 317
318
MST1/2 overexpression does not affect the proliferation of HPV-cancer cells 319
As we did not observe a significant decrease in MST1 expression in the HPV-C33A 320 cells compared with NHK controls (Figure 1) , we assessed whether MST1 or MST2 321 overexpression could still regulate their proliferation. Despite clear activation of the 322 Figure 3A Figure 4A ). Importantly, treatment of HeLa or CaSKi with XMU-336 MP1 prevented MST1 or MST2-mediated nuclear exclusion of YAP1 ( Figure 6B and 337 Supplementary Figure 4B , white arrows). 338
Hippo pathway in these cells upon MST overexpression (Supplementary
To confirm our observations with XMU-MP1, we introduced either kinase dead MST1 339 (K59R) or MST2 (K56R) into HPV+ cancer cells. Mutant proteins failed to increase 340 the phosphorylation of MOB compared with wild type (WT) controls ( Figure 7A and 341 Supplementary Figure 5A ). Furthermore, the mutants failed to redistribute YAP from 342 the nucleus to the cytoplasm ( Figure 7B and Supplementary Figure 5B and D). To test if this effect was due to MST1/2 kinase activity, we utilised XMU-MP1 361 and the MST1/2 kinase dead mutants. In contrast to untreated cells overexpressing 362 MST1/2, cells treated with XMU-MP1 or expressing kinase dead MST1/2 mutants did 363 not show a decrease in migration or invasion. Taken together, this demonstrates that 364
MST1/2 negatively regulate migration and invasion of cervical cancer cells in a 365
kinase-dependent manner. 366
Discussion 368
Despite the current availability of prophylactic vaccines against HPV, there are no 369 specific anti-viral therapies for HPV-associated cancers. Therefore, research is still 370 required to understand the virus-host interactions found in these cancers and to 371 identify the host factors essential for transformation in order to identify targets for 372 therapeutic intervention. The Hippo pathway has emerged as a key signalling 373 pathway deregulated in many cancers (31). As the canonical activator of the Hippo 374 pathway, the MST1 kinase is down-regulated in several cancers and has been 375 shown to serve as a negative regulator of tumourigenesis (16, 17) . In this study, we 376 used a combination of HPV+ cancer cell lines and patient samples to provide the first 377 evidence that MST1 expression is down regulated in HPV+ cervical cancer. 378
Our data demonstrates that the HPV E6 and E7 oncoproteins regulate MST1 379 expression. These oncoproteins have well defined roles to inhibit the function of 380 critical tumour suppressors. The inactivation of p53 and pRb by E6 and E7, 381 respectively, is thought to be a critical step in cervical cancer progression (25,26). In 382 spite of this dogma, E6 mutants exist that are unable to degrade p53 but still 383 transform cells (32). Moreover, inhibition of pRb and its family members is 384 insufficient to initiate cervical cancer (33). These findings highlight the complex 385 nature of virus-mediated transformation and suggest that perturbation of multiple 386 host factors is required for cervical cancer progression. 387
The Hippo pathway converges on the transcription factor YAP1 -a key mediator of 388 cell proliferation that is deregulated in many cancers, including cervical cancer (19) . 389
Importantly, we show that overexpression of MST1 in HPV+ cervical cancer cells 390 leads to an inhibition of YAP1 function, as seen by increased pYAP (S127), and a 391 corresponding decrease in cell proliferation (Figure 4) . Recently, it has been 392 demonstrated that HPV16 E6 stabilises the YAP1 protein to enable increased EGFR 393 signalling. This might be achieved by up-regulating expression of EGFR and its 394 ligand amphiregulin, resulting in increased cell proliferation (19) . We show that the 395 overexpression of MST1 also down regulates the expression of amphiregulin and 396 this may be a mechanism by which MST1 inhibits cell proliferation. 397
Our data demonstrates that HPV regulates MST1 mRNA levels (Figure 2 and 3) . 398
These findings are supported by clinical data, showing that MST1 mRNA expression 399 negatively correlates with cervical disease progression and data from publicly 400 available databases shows that MST1 mRNA expression is also down regulated in 401 cervical cancer (Figure 1) . Thus far the mechanisms by which HPV impairs MST1 402 expression are not understood. Whilst our knockdown studies show that loss of 403 either E6 or E7 correlates with increased MST1 protein expression, qRT-PCR 404 analysis indicates that E7 is predominantly responsible for repressing MST1 405 transcription. In head and neck carcinoma expression from the MST1 gene is down 406 regulated via methylation of its promoter (34). DNA methylation leads to the 407 formation of heterochromatin, an inactive form of DNA, preventing gene expression 408 (35). DNA methylation is an important process in development and alterations in 409 DNA methylation patterns are associated with the development of cancer (36). Given 410 that the HPV oncoproteins have previously been reported to alter levels of host DNA 411 methylation to promote transformation (37), future research will investigate if the 412 MST1 promoter is methylated in HPV+ cervical cancer to ascertain a mechanism for 413 MST1 mRNA down regulation. Studies will also need to address whether E6 also 414 regulates MST1 protein expression directly. Since E6 interacts with proteins from the 415 ubiquitination system its expression could lead to the degradation of MST1 in 416 cervical cancers. 417
In summary, our study has demonstrated that the tumour suppressor MST1 is down 418 regulated at the transcript level in HPV positive cervical cancer, leading to 419 dysregulation of the Hippo pathway ( Figure 9 ). We show that overexpression of 420 MST1, and its paralogue MST2, activates the Hippo pathway, resulting in the 421 inhibition of cell proliferation and colony formation ability. Our observations provide 422 further support for targeting the Hippo pathway in HPV positive cervical cancers. 423 424
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